Kimura S - Search Results

1

Ever-advancing chronic myeloid leukemia treatment.

Kimura S, Ando T, Kojima K. Kimura S, et al. Int J Clin Oncol. 2014 Feb;19(1):3-9. doi: 10.1007/s10147-013-0641-7. Epub 2013 Nov 22. Int J Clin Oncol. 2014. PMID: 24258348 Review.

2

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.

Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T. Kimura S, et al. Int J Hematol. 2004 Jan;79(1):37-43. doi: 10.1007/BF02983531. Int J Hematol. 2004. PMID: 14979476

3

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T. Kimura S, et al. Blood. 2005 Dec 1;106(12):3948-54. doi: 10.1182/blood-2005-06-2209. Epub 2005 Aug 16. Blood. 2005. PMID: 16105974 Free article.

4

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. Yokota A, et al. Among authors: kimura s. Blood. 2007 Jan 1;109(1):306-14. doi: 10.1182/blood-2006-03-013250. Epub 2006 Sep 5. Blood. 2007. PMID: 16954504 Free article.

5

New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Kimura S, Ashihara E, Maekawa T. Kimura S, et al. Curr Pharm Biotechnol. 2006 Oct;7(5):371-9. doi: 10.2174/138920106778521532. Curr Pharm Biotechnol. 2006. PMID: 17076652 Review.

6

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S. Maekawa T, et al. Among authors: kimura s. Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review.

7

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. Kuroda J, et al. Among authors: kimura s. Br J Haematol. 2008 Jan;140(2):181-90. doi: 10.1111/j.1365-2141.2007.06899.x. Epub 2007 Nov 20. Br J Haematol. 2008. PMID: 18028486 Free article.

8

Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone.

Kimura S. Kimura S. Recent Pat Anticancer Drug Discov. 2006 Nov;1(3):347-55. doi: 10.2174/157489206778776907. Recent Pat Anticancer Drug Discov. 2006. PMID: 18221045 Review.

9

Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.

Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Morinaga K, et al. Among authors: kimura s. Int J Cancer. 2008 Jun 1;122(11):2621-7. doi: 10.1002/ijc.23435. Int J Cancer. 2008. PMID: 18338755

10

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.

Tanaka R, Kimura S. Tanaka R, et al. Among authors: kimura s. Expert Rev Anticancer Ther. 2008 Sep;8(9):1387-98. doi: 10.1586/14737140.8.9.1387. Expert Rev Anticancer Ther. 2008. PMID: 18759691 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,888 results

Search Page

Filters